OTC: PKTX

The information discussed in this Annual Report
on Form 10-K for the fiscal year ended December 31, 2024 as well as some statements in press releases and some oral statements of the
Company’s officers during presentations about the Company include “forward looking statements” within the meaning of
Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the
“Exchange Act”). All statements, other than statements of historical facts, included herein and therein concerning,
among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our
financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward
looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,”
“project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,”
“will,” “continue,” “potential,” “should,” “could,” and similar terms and
phrases. Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve
certain assumptions, risks and uncertainties and are not (and should not considered to be) guarantees of future performance. Our results
could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, among others:

•
Our capital requirements and the uncertainty of being able to obtain additional funding on terms acceptable to us;

•
Our plans to develop and commercialize products from the AAGP® molecule;

•
Ongoing testing of the AAGP® molecule;

•
Our intellectual property position;

•
Our commercialization, marketing and manufacturing capabilities and strategy;

•
Our ability to retain key members of our senior management and key scientific consultants;

•
The effects of competition;

•
Our potential tax liabilities resulting from conducting business in the United States and Canada;

•
The effect of further sales or issuances of our common stock and the price and volume volatility of our common stock; and our common stock’s limited trading history.

3

Finally, our future results will depend upon various
other risks and uncertainties, including, but not limited to, those detailed in the section entitled “Risk Factors” included
elsewhere in this Annual Report. All forward looking statements attributable to us or persons acting on our behalf are expressly
qualified in their entirety by the cautionary statements in this section and elsewhere in this Annual Report. Other than as required
under securities laws, we do not assume a duty to update these forward looking statements, whether as a result of new information, subsequent
events or circumstances, changes in expectations or otherwise.

Recent Developments

On June 6, 2023,
the Company announced the submission of a research paper describing cell characterization, graft evaluation, and yield of islet-like cells
differentiated from patient-derived iPSCS for the treatment and eventual cure of Type-1 Diabetes for publication in Transplantation.

Research and Development

Our business depends on our ability to sponsor research
and development activities. For the year ended December 31, 2023, the Company incurred total research and development expenses of
$112,444. For the year ended December 31, 2024, the Company incurred total research and development expenses of $99,625. In
order to reach the Company’s goals of developing a marketable product, we will need to increase the funding of our research and
development activities which at this time is limited by our ability to raise money to fund the Company.